Verve Therapeutics
Biotechnology ResearchMassachusetts, United States51-200 Employees
Verve Therapeutics is a biotechnology company focused on cardiovascular genetic medicines that aim to transform treatment from long-term, chronic regimens to single-course gene-editing therapies. It operates as a wholly owned subsidiary of Eli Lilly and Company and is based in Boston, Massachusetts. The lead programs—VERVE-102, VERVE-201, and VERVE-301—seek to permanently turn off liver genes associated with atherosclerotic risk, targeting PCSK9, ANGPTL3, and LPA to influence LDL cholesterol, triglyceride-rich lipoproteins, and lipoprotein(a). These therapies are designed for patients with established cardiovascular disease in whom current treatments leave LDL cholesterol or related risk factors insufficiently controlled, including individuals with various forms of familial hypercholesterolemia. Within the biotechnology sector, Verve is positioned as a developer of next-generation genetic medicines for cardiovascular disease, leveraging gene-editing approaches to address underlying drivers of atherosclerosis. In 2024, the company was recognized as a Top Place to Work by The Boston Globe for the fourth consecutive year, reflecting its local impact.
1-888-653-2347 
support@leadiq.com 
